Capital Research Global Investors
RYZB

Capital Research Global Investors’s RayzeBio, Inc. Common Stock RYZB Stock Holding History

Capital Research Global Investors’s Portfolio RYZB Stock Details RYZB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-170,808
Closed -$10.6M – 433
2023
Q4 		$10.6M Sell
170,808
-1,079,192
-86% -$26.8M ﹤0.01% 384
2023
Q3 		$27.8M Buy
+1,250,000
New +$26.2M 0.01% 357

Capital Research Global Investors's RYZB Position: Q1 2024 in Review

Capital Research Global Investors sold out of RayzeBio, Inc. Common Stock (RYZB) in Q1 2024, closing a stake of 170,808 shares — an estimated $10.6M sold.

Capital Research Global Investors first reported a position in RYZB in Q3 2023 and held it in 2 quarters. The position peaked at $27.8M in Q3 2023. 0 funds tracked by Wall St. Rank hold RYZB as of Q1 2024.

  • Capital Research Global Investors reported no remaining RayzeBio, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Capital Research Global Investors sold 170,808 RayzeBio, Inc. Common Stock shares in Q1 2024, an estimated $10.6M.
  • Capital Research Global Investors first reported a position in RayzeBio, Inc. Common Stock in Q3 2023 and held it in 2 quarters.
  • Capital Research Global Investors's RayzeBio, Inc. Common Stock position peaked at $27.8M in Q3 2023.
  • 0 funds tracked by Wall St. Rank held RayzeBio, Inc. Common Stock as of Q1 2024.

Based on Capital Research Global Investors's 13F filing for Q1 2024, filed 14 May 2024.